NUOVE FRONTIERE NELLA PREVENZIONE E GESTIONE DI OBESITÀ E DIABETE

1. 1.American Diabetes Association Professional Practice Committe. Standards of Care in Diabetes. 2026. Diabetes Care. 2026;49(Suppl 1):S1-S400. 2026
   Standards of Care in Diabetes
   LibroCerca su Amazon
2. 2.Frias JP, Pratley RE, Kadowaki T, Bajaj HS, Lingvay I, Chan JCN, et al.. Oral orfoglipron for early type 2 diabetes management. N Engl J Med. 2025;392(8):721-733. 2025
   Articolo scientificoN Engl J Med. 2025;392(8):721-733Cerca su Google Scholar
3. 3.AAVV (key global experts such as Sofia B. Ahmed, Juan Jesus Carrero, Bethany Foster, Anna Francis, Rasheeda K. Hall, Will G. Herrington, Guy Hill, and Rümeyza Kazancioglu). Kidney Disease: Improving Global Outcomes (KDIGO) CKD Guideline Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4 Suppl):S1-S150. 2024
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD Guideline Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
   LibroCerca su Amazon
4. 4.McGuire DK, Shih WJ, Cosentino F, Cherney DZI, Dagogo-Jack S, Charbonnel B, et al.. Cardiovascular and kidney outcomes with SGLT2 inhibitors in type 2 diabetes: updated evidence.. Circulation. 2024;149(5):356-370. 2024
   Articolo scientificoCirculation. 2024;149(5):356-370Leggi il PDF gratuito

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).